NewsAussie pharma CSL in talks to buy Swiss firm...

Aussie pharma CSL in talks to buy Swiss firm Vifor Pharma for USD 7B

-

CSL, the Australian giant, is in talks to buy Vifor Pharma in a deal that is valued at $7B, or A$10B. Vifor Pharma is a Swiss pharma company.
Analysts predict that as CSL buys Vifor Pharma it will be able to expand on its current portfolio to include manufacturing of drugs for kidney and heart disease. Currently, CSL pharmaceutical company is the largest manufacturer of blood plasma treatments.
The deal has been in the works since early 2021, but as the talks have become serious, Vifor Pharma’s shares have risen by almost a fifth, closing in at a 21% increase in the Swiss index.
CSL pharmaceutical company had seen a dip in collections for plasma due to COVID-19 pandemic restrictions. This is due to the fact that it is dependent on people coming for blood to be purchased by the company.
As CSL buys Vifor pharma, they will gain the ability to expand on their kidney transplant franchise, which is currently in its infancy stage. However, this will be a step away from their focus on the therapeutic area of medicine. Both companies have stated that they will not be commenting on the deal.

Life Sciences Voice Logo mobile
+ posts

Latest news

Dysport Meets Phase 3 Goals in Episodic and Chronic Migraine Trials

Ipsen announced that its neurotoxin Dysport achieved the primary goals in two Phase 3 clinical trials evaluating the treatment...

J&J Reports Positive Phase 2/3 Results for Imaavy in Warm Autoimmune Hemolytic Anemia

Johnson & Johnson has reported results from the pivotal phase 2/3 Energy study evaluating Imaavy in patients with warm...

Edgewise Reports Phase 2 CIRRUS-HCM Results for EDG-7500 Ahead of Planned Phase 3 Development

Edgewise Therapeutics has reported top-line results from Part D of the Phase 2 CIRRUS-HCM trial evaluating EDG-7500 in patients...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you